在治疗克罗恩病相关性黏膜溃疡中应用英夫利昔单抗定期维持治疗优于间断治疗

2022-12-25 05:03:20 第一文档网 [ 字体：小中大 ] [ 阅读： ] [

【#第一文档网# 导语】以下是®第一文档网的小编为您整理的《在治疗克罗恩病相关性黏膜溃疡中应用英夫利昔单抗定期维持治疗优于间断治疗》，欢迎阅读！
治疗,克罗恩,黏膜,相关性,优于
在治疗克罗恩病相关性黏膜溃疡中应用英夫利昔单抗定期维持

治疗优于间断治疗

Rutgeerts; P.; Diamond; R.; H.; Bala; M.; 郝筱倩（译）; 郑世成（校）

【期刊名称】《《世界核心医学期刊文摘：胃肠病学分册》》【年(卷),期】2006(002)008

【摘要】Background: The endoscopic substudy of the ACCENT I (A Crohn’s Disease Clinical Trial Evaluating Infliximab in a New Long-term Treatment Regimen) Crohn’s disease trial examined the effects of infliximab on mucosal inflammation and mucosal healing, and assessed their impact on outcomes. Design: ACCENT I was a randomized, double-blind, parallel group study. Setting: This study took place at multiple centers in North America, Europe, and Israel. Main Outcome

Measurements: Ileocolonoscopic examinations were performed at weeks 0, 10, and 54. Complete mucosal healing was defined as the Absence of all mucosal ulcerations. The end point of principal interest was the proportion of patients randomized as responders with mucosal healing at week 10. The proportion of responderswho demonstrated mucosal healing at week 54 or at both weeks 10 and 54 is also summarized. Changes in Crohn’s disease endoscopic index of severity (CDEIS) scores from baseline to week 10 and 54 were calculated for all patients in this substudy. Results:

Complete mucosal healing by week 10 occurred in significantly more week 2 responders who had received 3 doses of infliximab compared with a

single dose (31% vs. 0% , p = 0.010). A significantly higher proportion of week 2 responders in the combined scheduled maintenance group had complete mucosal healing at week 54 compared with the episodic group (50% vs. 7% , p = 0.007). The results for all patients are consistent with those for week 2 responders only. Significantly greater improvement in the CDEIS occurred with scheduled maintenance compared with episodic treatment at week 10 (p ≤ 0.001) and week 54 (p = 0.026). Notably, no strong relationship between clinical remission and complete mucosal healing was found. Overall, mucosal healing appeared to correlate with fewer hospitalizations, although these results were not statistically significant. Conclusions: Scheduled infliximab maintenance therapy resulted in more improvement in mucosal ulceration and in higher rates of mucosal healing. There was a numerical trend for patients with better mucosal healing to have a lower rate of Crohn’s disease-related hospitalizations. 【总页数】2页(P30-31)

【作者】Rutgeerts; P.; Diamond; R.; H.; Bala; M.; 郝筱倩（译）; 郑世成（校）【作者单位】Universita; r; Ziekenhuis; Gasthuisberg; Afdeling; Gastroenterologie; Leuven; Belgium; 不详【正文语种】中文【中图分类】R699.2 【相关文献】

1.肺癌化疗相关性口腔黏膜炎治疗中rhg-Csf的应用 [J], 张建

2.血清英夫利西单抗谷浓度、抗英夫利西单抗抗体水平监测在英夫利西单抗维持治疗克罗恩病患者中的临床应用 [J], 张启维;孙颖;王天蓉;沈骏;冉志华;郑青 3.微生态制剂联合氨基水杨酸类药物在溃疡性结肠炎维持治疗中的应用研究 [J], 卢彬彬

4.直肠黏膜间断缝扎注射术在直肠黏膜脱垂治疗中的应用 [J], 朱军;丁健华;汤海燕;赵玉涓;赵克

5.英夫利昔单抗-类克在激素抵抗及激素依赖溃疡性结肠炎治疗中的应用 [J], 李懿璇;李世荣;李俊霞;杨欣艳;王化虹

因版权原因，仅展示原文概要，查看原文内容请购买